Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023)
Vaccine effectiveness (VE) of quadrivalent live attenuated influenza vaccine (LAIV4) and quadrivalent inactivated influenza vaccine (IIV4) in children in 13 European countries and the US during the 2019–2023 influenza seasons was evaluated from published literature, congress presentations, public he...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Vaccine: X |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136225000609 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399190827827200 |
|---|---|
| author | Allyn Bandell George Kassianos Oliver Dibben Georges El Azzi |
| author_facet | Allyn Bandell George Kassianos Oliver Dibben Georges El Azzi |
| author_sort | Allyn Bandell |
| collection | DOAJ |
| description | Vaccine effectiveness (VE) of quadrivalent live attenuated influenza vaccine (LAIV4) and quadrivalent inactivated influenza vaccine (IIV4) in children in 13 European countries and the US during the 2019–2023 influenza seasons was evaluated from published literature, congress presentations, public health websites, and personal communications with investigators.A meta-analysis was performed by assessing LAIV4 and/or IIV4 VE in children (N = 34–1679) across included studies during the 2019/20–2022/23 seasons. VE estimates against influenza infection (all strains) for LAIV4 were 61.9 % (95 % confidence interval [CI]: 53.0–69.1) and for IIV4 were 45.7 % (33.2–55.8). Overall VE (95 % CI) for individual strains for the 2022/23 season for LAIV4 were 75.7 % (52.0–87.7) and for IIV4 were 58.5 % (38.2–72.1).Overall, LAIV4 and IIV4 VE in children was moderate and comparable. Annual vaccination with LAIV4 or IIV4 remains the best way to protect children against influenza infection. |
| format | Article |
| id | doaj-art-0e20cccdf20d4c09a6895fc30ded7f00 |
| institution | Kabale University |
| issn | 2590-1362 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Vaccine: X |
| spelling | doaj-art-0e20cccdf20d4c09a6895fc30ded7f002025-08-20T03:38:24ZengElsevierVaccine: X2590-13622025-08-012510066610.1016/j.jvacx.2025.100666Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023)Allyn Bandell0George Kassianos1Oliver Dibben2Georges El Azzi3US Medical Affairs, AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 0878, USA; Corresponding author.Royal College of General Practitioners and British Global & Travel Health, Wokingham, UKFlu-BPD, Biopharmaceutical Development, R&D, AstraZeneca, Renaissance Way, Speke, Liverpool, L24 9JW, UKMedical, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, 1 Francis Crick Ave, Trumpington, Cambridge CB2 0AA, UKVaccine effectiveness (VE) of quadrivalent live attenuated influenza vaccine (LAIV4) and quadrivalent inactivated influenza vaccine (IIV4) in children in 13 European countries and the US during the 2019–2023 influenza seasons was evaluated from published literature, congress presentations, public health websites, and personal communications with investigators.A meta-analysis was performed by assessing LAIV4 and/or IIV4 VE in children (N = 34–1679) across included studies during the 2019/20–2022/23 seasons. VE estimates against influenza infection (all strains) for LAIV4 were 61.9 % (95 % confidence interval [CI]: 53.0–69.1) and for IIV4 were 45.7 % (33.2–55.8). Overall VE (95 % CI) for individual strains for the 2022/23 season for LAIV4 were 75.7 % (52.0–87.7) and for IIV4 were 58.5 % (38.2–72.1).Overall, LAIV4 and IIV4 VE in children was moderate and comparable. Annual vaccination with LAIV4 or IIV4 remains the best way to protect children against influenza infection.http://www.sciencedirect.com/science/article/pii/S2590136225000609InfluenzaVaccine effectivenessChildren |
| spellingShingle | Allyn Bandell George Kassianos Oliver Dibben Georges El Azzi Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023) Vaccine: X Influenza Vaccine effectiveness Children |
| title | Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023) |
| title_full | Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023) |
| title_fullStr | Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023) |
| title_full_unstemmed | Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023) |
| title_short | Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023) |
| title_sort | comparative effectiveness of live attenuated influenza vaccine laiv and inactivated influenza vaccine iiv in children over multiple influenza seasons 2019 2023 |
| topic | Influenza Vaccine effectiveness Children |
| url | http://www.sciencedirect.com/science/article/pii/S2590136225000609 |
| work_keys_str_mv | AT allynbandell comparativeeffectivenessofliveattenuatedinfluenzavaccinelaivandinactivatedinfluenzavaccineiivinchildrenovermultipleinfluenzaseasons20192023 AT georgekassianos comparativeeffectivenessofliveattenuatedinfluenzavaccinelaivandinactivatedinfluenzavaccineiivinchildrenovermultipleinfluenzaseasons20192023 AT oliverdibben comparativeeffectivenessofliveattenuatedinfluenzavaccinelaivandinactivatedinfluenzavaccineiivinchildrenovermultipleinfluenzaseasons20192023 AT georgeselazzi comparativeeffectivenessofliveattenuatedinfluenzavaccinelaivandinactivatedinfluenzavaccineiivinchildrenovermultipleinfluenzaseasons20192023 |